Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Frank, Struyf"'
Autor:
Hui Xiao, Xiangbin Lu, Yanqiu Zhang, Zhilong Ma, Frank Struyf, Naveen Karkada, Yabin Xu, Nicolas Folschweiller, Johny Jiang, Yan Xie, Yunyu Jiang, Archana Jastorff, Dorota Borys, Yuemei Hu, Yilin He, Sylviane Poncelet, Xiang Zhang
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim In 9‐17‐year‐old Chinese girls, the AS04‐adjuvanted HPV‐16/18 vaccine (AS04‐HPV‐16/18) given as three‐dose schedule induced high antibody levels, which were noninferior 1 month after the third dose to those observed in 18‐25‐y
Autor:
Kari Natunen, Mari Hokkanen, Tuomas Lehtinen, Frank Struyf, Dan Bi, Tiina Eriksson, Silvia Damaso, Matti Lehtinen, Katja Harjula, Dan Apter, Maaria Soila
Publikováno v:
International Journal of Cancer
We studied effectiveness of the AS04‐adjuvanted HPV‐16/18 (AS04‐HPV‐16/18) vaccine against human papillomavirus (HPV) oropharyngeal infections associated with the increase of head/neck cancers in western countries. All 38,631 resident adolesc
Autor:
Fengcai Zhu, Qin-Jing Pan, Jia-Xi Yu, Frank Struyf, Ying Hong, Yunkun He, Shang-Ying Hu, Naveen Karkada, Yuemei Hu, Yi-Ju Zhang, Yan-Shu Zhang, Xiaoping Yang, Haiwen Tang, Cheng-Fu Zhang, Feng Chen, P.V. Suryakiran, Dan Bi, Jun Bi, Changrong Wang, Fang-Hui Zhao, Xun Zhang, Lingling Shen, Qian Zhang, Hong Wang, Shiyin Xue, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu
Publikováno v:
Cancer Medicine, Vol 8, Iss 14, Pp 6195-6211 (2019)
Cancer Medicine
Cancer Medicine
Background Cervical cancer is a major public health concern in China. We report the end‐of‐study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the AS04‐human papillomavirus (HPV)‐16/18 vaccine in Chines
Autor:
Tiina Petäjä, Simopekka Vänskä, Tiina Eriksson, Jorma Paavonen, Matti Lehtinen, Pekka Nieminen, Katja Harjula, Maaria Soila, Eero Pukkala, Frank Struyf, Kari Natunen, Dan Apter, Johanna Palmroth, Mari Hokkanen, Brigitte Cheuvart, Dan Bi
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7759-7771 (2021)
Cancer Medicine
Cancer Medicine
Introduction We conducted a community‐randomized trial (NCTBLINDED) in Finland to assess gender‐neutral and girls‐only vaccination strategies with the AS04‐adjuvanted human papillomavirus (HPV)‐16/18 (AS04‐HPV‐16/18)vaccine. Methods Gir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8fc63a95f9acc2c6e1d7df61bc7f3b
http://hdl.handle.net/10138/336609
http://hdl.handle.net/10138/336609
Autor:
Maria Rowena Del Rosario-Raymundo, Gary Dubin, Céline Bouchard, Jorge Salmerón, Margaret E. Cruickshank, Frank Struyf, Tanya Stoney, Shelly A. McNeil, Xavier Castellsagué, Marie Cecile Bozonnat, Alison Fiander, Galina Minkina, Bram ter Harmsel, Alevtina Savicheva, Suzanne M. Garland, Deborah Money, Arunachalam Ilancheran, Mark G. Martens, Carlos S. Vallejos, Dominique Rosillon, Timothy Yong Kuei Lim, Kah Leng Fong, Cosette M. Wheeler, S R Skinner, Eduardo Lazcano-Ponce, Laurence Baril, Archana Chatterjee, Swee Chong Quek
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Cancer Medicine, Vol 8, Iss 10, Pp 4938-4953 (2019)
Background Infections with human papillomavirus (HPV) types 16 and 18 account for ~70% of invasive cervical cancers but the degree of protection from naturally acquired anti‐HPV antibodies is uncertain. We examined the risk of HPV infections as def
Autor:
Ying Hong, Haiwen Tang, Fengcai Zhu, Shang-Ying Hu, Qin-Jing Pan, Cheng-Fu Zhang, Yuemei Hu, Xiaoping Yang, Xiaoqian Xu, Feng Chen, Fang-Hui Zhao, Dan Bi, Jia-Xi Yu, Shuang Zhao, Wen-hua Zhang, Jiahong Zhu, Yejiang Zhu, Xun Zhang, Frank Struyf, Naveen Karkada
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-H
Autor:
Sarah Tete, Anna Marit de Groot, Carla Truyers, Jeroen N Stoop, Pierre Van Damme, Wim Van Damme, M. Juliana McElrath, Isabel Leroux-Roels, Mathieu Le Gars, Georgi Shukarev, Pieter-Jan Berghmans, Macaya Douoguih, Frank Struyf, Kristen W. Cohen, Emmanuel Cormier, Murray A Kimmel, Kathryn E. Stephenson, Dirk Heerwegh, Jerry Sadoff, Stephen C. De Rosa, Jan de Hoon, Gert Scheper, Johan Van Hoof, Jenny Hendriks, Dan H. Barouch, Hanneke Schuitemaker, William I. Smith
BACKGROUNDThe ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dc5c432de05a2b06ee17c4d15799a77
https://doi.org/10.1101/2020.09.23.20199604
https://doi.org/10.1101/2020.09.23.20199604
Autor:
Mark Schiffman, Allan Hildesheim, Frank Struyf, Matti Lehtinen, Aimée R. Kreimer, Paula N. Gonzalez, Naveen Karkada, Carolina Porras, Wim Quint, John T. Schiller, Joseph E. Tota, Cosette M. Wheeler, Martin Ryser, John Schussler, Nicolas Folschweiller, Joshua N. Sampson, Ana Cecilia Rodriguez, Rolando Herrero
Publikováno v:
J Infect Dis
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933100ecc1d04e70bdb2f618f4b1a38c
https://europepmc.org/articles/PMC8248553/
https://europepmc.org/articles/PMC8248553/
Autor:
Luis Romano-Mazzotti, Frank Struyf, Adriana Luque, Albino Salas Cespedes, Maria Angelica Granados, Maria Mercedes Castrejon Alba, Lan Lin, Silvia Damaso, Victor Y Sierra, Mercedes Macías Parra
Publikováno v:
Pediatric Infectious Disease Journal. 37:e93-e102
BACKGROUND The burden of cervical cancer caused by human papillomavirus (HPV) is high in Latin America. The suboptimal HPV vaccination coverage in adolescents could be improved by pediatric immunization. HPV vaccination has not yet been reported in g
Autor:
Marjan Hezareh, Nicolas Folschweiller, Lars Rombo, Bee Wah Lee, Stéphanie De Simoni, Helen M. L. Oh, Franck Thollot, Ngiap Chuan Tan, Anthony P. Y. Liu, Fong Seng Lim, Roman Rouzier, Frank Struyf, Florence Thomas, P.V. Suryakiran, Ting Fan Leung
Publikováno v:
Vaccine. 36:98-106
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of two doses (2D) of the HPV-16/18 AS04-adjuvanted vaccine (2D of AS04-HPV-16/18) vs. two or three doses of the 4vHPV vaccine [2D or 3D of 4vHPV] in 107